Roche Has Blockbusters In Its Pipeline – But Demurs On Predicting Hits
Flurry Of Pivotal Data In 2020
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.
You may also be interested in...
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.
Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.
Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.